Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
To protect your results and your investment, our team will confirm the best plan during your consultation, including whether non-surgical tightening is appropriate or whether surgical options should be considered for significant excess skin.
For the full analysis inclusive of demographics, comorbidities, and social drivers of health data for the population, methodology, findings (including dispensing trends, which indicates whether the patient picked up the medication and can be a proxy for understanding medication adherence), limitations, and citations you can view the complete report on MedRxiv
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis
Insurance pathways: If insurance-covered GLP-1 medications are an option for you, does the platform also facilitate access to FDA-approved versions, or only compounded formulations
For those experiencing Ozempic face, it is a game changer